Publications by authors named "John Sims"

Claim this Profile
P
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Ming Lu, Min Jung Kim, Emily C Collins, Sergey Shcherbinin, Amy K Ellinwood, John R Sims

JAMA Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Jennifer A Zimmer, John R Sims, Cynthia D Evans, Emel Serap Monkul Nery, Hong Wang

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's Imaging Consortium.
Vikas Kotari, Karen Chilcott Holdridge, Roy Yaari, Melissa A M Williamson, John R Sims

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's Imaging Consortium.
Chris Conklin, Stefan Radonjic, David Scott, Madhura Ingalhalikar, Luc Bracoud, John R Sims

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's Imaging Consortium.
Ian A Kennedy, Min Jung Kim, Ming Lu, John R Sims, Mark A Mintun

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing Topics.
Ivelina Gueorguieva, Kay Hoong Chow, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, John R Sims

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers.
Vikas Kotari, Karen Chilcott Holdridge, Roy Yaari, Melissa A M Williamson, John R Sims

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer's disease.
Maura Malpetti, Saima Rathore, Leonardo Iaccarino, Renaud La Joie, Giulia Tronchin, John R Sims

Alzheimers Res Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, John R Sims

J Prev Alzheimers Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease.
Garrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, Greg Anglin, Jason Bailey, John R Sims

Alzheimers Dement (N Y)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3.
Roy Yaari, Karen C Holdridge, Melissa Williamson, Alette M Wessels, Sergey Shcherbinin, John R Sims

Alzheimers Dement· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab exposure-response in early symptomatic Alzheimer's disease.
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A Zimmer, John R Sims

Alzheimers Dement· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, John R Sims

JAMA Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.
Stephen Salloway, Andrew Pain, Elly Lee, Michelle Papka, Margaret B Ferguson, John R Sims

Alzheimers Dement· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, John R Sims

Alzheimers Dement· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.
Sandar Aye, Gunilla Johansson, Christoph Hock, Lars Lannfelt, John R Sims

J Prev Alzheimers Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.
Christopher Lloyd, Per-Ola Freskgård, Philip Newton, David Lowne, Adrian Nickson, John R Sims

Alzheimers Dement· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data.
Krista M Schroeder, Ana Sofia Afonso, Huabo Wang, Sarah Grace, Adam Phipps, John R Sims

J Alzheimers Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
Scott A Roof, James Jabalee, Eleni M Rettig, Susmita Chennareddy, Rocco M Ferrandino, John Sims

Oral Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Shoichiro Sato, Naohisa Hatakeyama, Shinji Fujikoshi, Sadao Katayama, Hideaki Katagiri, John R Sims

Neurol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, John R Sims

JAMA Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Adam S Fleisher, Leanne M Munsie, David G S Perahia, Scott W Andersen, Ixavier A Higgins, John R Sims

Neurology· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
Cynthia D Evans, John R Sims

JAMA· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.
Glenn J Hanna, Scott A Roof, Jamie Jabalee, Eleni M Rettig, Rocco Ferrandino, John Sims

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Sergey Shcherbinin, Amanda Morris, Ixavier A Higgins, Ilke Tunali, Ming Lu, John R Sims

Alzheimers Dement (N Y)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis